Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.470
+0.070 (5.00%)
Jun 4, 2025, 4:00 PM EDT
126.15%
Market Cap 73.63M
Revenue (ttm) n/a
Net Income (ttm) -64.37K
Shares Out 52.59M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,982
Average Volume 57,380
Open 1.450
Previous Close 1.400
Day's Range 1.440 - 1.470
52-Week Range 0.560 - 2.800
Beta n/a
RSI 48.19
Earnings Date Aug 1, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3′-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.